Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | TKT | P29401 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599129 | 0.88 | PNP (0.39) | PNP | |
| SCHEMBL26506 | 0.85 | SUMO1 (0.36) | PNP | |
| SCHEMBL2512344 | 0.85 | SUMO1 (0.36) | PNP | |
| SCHEMBL29512549 | 0.83 | SUMO1 (0.36) | PNP | |
| SCHEMBL356920 | 0.81 | BACE1 (0.39) | PNP | |
| SCHEMBL7601001 | 0.81 | HPGD (0.47) | PNP | |
| SCHEMBL7597747 | 0.80 | MPO (0.38) | CHEK1 | |
| SCHEMBL7607407 | 0.79 | MPO (0.40) | — | |
| SCHEMBL5491579 | 0.79 | TLR8 (0.44) | — | |
| Phosphoric Acid SCHEMBL29051947 | 0.79 | PNP (0.33) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195439-A1 | TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF | CURNA, INC. | 2022-06-23 | — | — | US | disclosed |
| US-11162139-B2 | Method for genomic profiling of DNA 5-methylcytosine and 5-hydroxymethylcytosine | SHANGHAI EPICAN GENETECH CO. LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
| CN-107941681-B | Method for identifying quantitative cellular composition in biological sample | 艾皮恩蒂斯有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-107002143-B | Epigenetic methods for identifying follicular helper T (TFH) cells | 艾芬特斯有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112236531-A | CXCR3 as epigenetic markers for identifying inflammatory immune cells, particularly CD8+ memory T cells | 精准医疗有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-105189783-B | Method for identifying quantitative cellular composition in biological sample | 艾皮恩蒂斯有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111315896-A | ERGIC1 as epigenetic marker for identifying immune cells, particularly monocyte myeloid-derived suppressor cells (mMDSC) | 艾皮恩蒂斯有限公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-111278988-A | Endosialin (CD248) as an epigenetic marker for identifying immune cells, in particular naive CD8+ T cells | 艾皮恩蒂斯有限公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-111247253-A | Amplicon region as epigenetic marker for identifying immune cells, particularly atypical monocytes | 艾皮恩蒂斯有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20190040394-A1 | TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF | CURNA, INC. | 2019-02-07 | — | — | US | disclosed |
| WO-2010115847-A1 | CONVERSION OF ALPHA-HYDROXYALKYLATED RESIDUES IN BIOMOLECULES USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2010-10-14 | — | — | WO | disclosed |
| EP-2210958-A2 | Real-time PCR point mutation assays for detecting HIV-1 resistance to antiviral drugs | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2003105754-A2 | ANTISENSE MODULATION OF VEGF-B EXPRESSION | ISIS PHARMACEUTICALS INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003102019-A2 | ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003053341-A2 | ANTISENSE MODULATION OF SHIP-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1212339-A4 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1212339-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014400-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-1996032403-A2 | NOVEL CYTOSINE AND CYTIDINE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-10-17 | — | — | WO | disclosed |
| WO-1984000759-A1 | DESOXYURIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANDOZ AG (AT) | 1984-03-01 | — | — | WO | disclosed |